XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.2

Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 21, 2015 USD ($)	Aug. 31, 2015 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Collaboration arrangements
License revenues from related party			$ 2,100	$ 2,100	$ 2,700	$ 4,600
Revenue			2,474	3,050	3,610	6,528
Minimum
Collaboration arrangements
Decrease in revenue					1,900
License revenues from related party
Collaboration arrangements
Revenue			2,108	2,123	2,665	4,574
Collaboration revenues from related party
Collaboration arrangements
Revenue			$ 366	$ 927	945	$ 1,954
BMS arrangement
Collaboration arrangements
Revenue					$ 355		$ 233
License revenue | Bristol Myers Squibb
Collaboration arrangements
Upfront payment recorded	$ 60,100
Expected performance term if no exclusivity					10 years
Average period for completion of pre-clinical phase					4 years
Average period for completion of clinical development and commercial launch					8 years 6 months
Percentage of increase in probability of all additional targets					10
License revenue | Bristol Myers Squibb | First Target Selection
Collaboration arrangements
Milestone payments to be received upon achievement					$ 254,000
License revenue | Bristol Myers Squibb | Second, Third, and Fourth Targets Selection
Collaboration arrangements
Target designation payment received		$ 15,000
License revenue | Bristol Myers Squibb | Fifth through Tenth Targets Selection
Collaboration arrangements
Maximum target designation payments to which entitled per agreement					16,500
License revenue | Bristol Myers Squibb | Other Selected Targets
Collaboration arrangements
Milestone payments to be received upon achievement					$ 217,000

X

- Definition

Represents the average period for completion of clinical development and commercial launch.

+ References

No definition available.

+ Details

Name:	qure_AveragePeriodForCompletionOfClinicalDevelopmentAndCommercialLaunch
Namespace Prefix:	qure_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the average period for completion of pre-clinical phase.

+ References

No definition available.

+ Details

Name:	qure_AveragePeriodForCompletionOfPreClinicalPhase
Namespace Prefix:	qure_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the decrease in revenue due to increase in probability of all additional targets.

+ References

No definition available.

+ Details

Name:	qure_DecreaseInRevenueDueToIncreaseInProbabilityOfAllAdditionalTargets
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The expected performance period for the license.

+ References

No definition available.

+ Details

Name:	qure_LicenseExpectedPerformanceTerm
Namespace Prefix:	qure_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned from related parties during the period relating to licenses.

+ References

No definition available.

+ Details

Name:	qure_LicenseRevenueFromRelatedParties
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The maximum target designation payments to which the reporting entity is entitled per agreement.

+ References

No definition available.

+ Details

Name:	qure_MaximumTargetDesignationPaymentsToWhichEntitledPerAgreement
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Milestone payments to be received upon achievement.

+ References

No definition available.

+ Details

Name:	qure_MilestonePaymentsToBeReceivedUponAchievement
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the percentage of increase in probability of all additional targets.

+ References

No definition available.

+ Details

Name:	qure_PercentageOfIncreaseInProbabilityOfAllAdditionalTargets
Namespace Prefix:	qure_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The target designation payment received.

+ References

No definition available.

+ Details

Name:	qure_TargetDesignationPaymentReceived
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The up-front payment received as of the effective date of the collaboration agreement,

+ References

No definition available.

+ Details

Name:	qure_UpfrontPaymentReceived
Namespace Prefix:	qure_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=qure_LicenseRevenueFromRelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=qure_CollaborativeRevenueFromRelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=qure_CollaborativeArrangementLicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=qure_BristolMyersSquibbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=qure_FirstTargetSelectionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=qure_SecondThirdAndFourthTargetsSelectionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=qure_FifthThroughTenthTargetsSelectionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=qure_OtherSelectedTargetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: